Inclusion criteria |
1. Signed informed consent |
2. Patients on maintenance hemodialysis for 90 days or longer |
3. Men or women aged ≥20 and ≤80 years old |
4. No treatment with VDRAs for more than 4 weeks prior to this study |
5. Serum calcium level ≤10.0 mg/dL |
6. Serum phosphate level ≤6.0 mg/dL |
7. Serum intact PTH level ≤180 pg/mL |
Exclusion criteria |
1. History within 12 weeks of myocardial infarction, stroke, aortic dissection/rupture, amputation of a lower limb, coronary revascularization or bypass surgery, lower limb revascularization or bypass surgery |
2. Heart failure of NYHA grade III or IV |
3. Respiratory failure with PaO2 <60 mmHg or SpO2 <90 % |
4. Life expectancy shorter than 1 year due to known malignant, infectious, or other diseases |
5. Abnormal liver function tests exceeding ×3 upper normal limits |
6. Pregnant or lactating females or females planning to be pregnant |
7. History of an allergic reaction to alfacalcidol |
8. Participation to other interventional studies within 12 weeks prior to this study |
9. Inappropriate for this study as judged by an attending investigator |